ProBioGen Expands Protein and Viral Manufacturing to Drive Continued Growth
Berlin, Germany, January 7, 2025 ProBioGen today announces the expansion of both protein and virus manufacturing at its Berlin headquarters. This includes the commissioning of an..
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development
Strasbourg (France), Berlin (Germany), November 5, 2024 Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment..
ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development
Berlin, Germany - May 29, 2024 ProBioGen, a leading contract development and manufacturing organization (CDMO), known for its innovative solutions in cell engineering and..
Change in Management
Berlin, Germany - April 30, 2024 ProBioGen AG (Berlin/Germany), a premier Contract Development and Manufacturing Organization (CDMO) and technology provider with extensive..
ProBioGen and DIOSynVax Partner to Manufacture Groundbreaking Multivalent Vaccine for Hemorrhagic Fever
Berlin, Germany - March 27, 2024 ProBioGen, a globally recognized and experienced Contract Development & Manufacturing Organization (CDMO), proudly announces a partnership with..
ProBioGen Partners with MAPP BIOPHARMACEUTICAL, INC. for Groundbreaking Development of Afucosylated Antibody Against Marburg Virus Disease Using GlymaxX Technology
Berlin, Germany - March 13th, 2024 ProBioGen, a leading CDMO of innovative solutions and services for biopharmaceutical development, is pleased to announce the execution of..
ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded Portfolio
Feb 4, 2025
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development
Nov 5, 2024
ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development
May 29, 2024
ProBioGen and DIOSynVax Partner to Manufacture Groundbreaking Multivalent Vaccine for Hemorrhagic Fever
Mar 27, 2024
ProBioGen Partners with MAPP BIOPHARMACEUTICAL, INC. for Groundbreaking Development of Afucosylated Antibody Against Marburg Virus Disease Using GlymaxX Technology
Mar 13, 2024
GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development
Sep 26, 2023
ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients
Apr 12, 2023
